**BC Cancer Protocol Summary for Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women with High Risk Early Stage Breast Cancer**

**Protocol Code** BRAJLHRHAI

**Tumour Group** Breast

**Contact Physician** Dr. Vanessa Bernstein

**ELIGIBILITY:**
- Premenopausal women (defined as those who have menstruated in the last 12 months OR who are biochemically premenopausal pre/post neoadjuvant or adjuvant chemotherapy) aged 50 years or younger with hormone receptor positive stage I-III operable breast cancer who have received neoadjuvant or adjuvant chemotherapy
- Premenopausal patients 35 years of age or younger with hormone receptor positive stage I-III operable breast cancer who decline chemotherapy
- Premenopausal women (defined as those who have menstruated in the last 12 months or who are biochemically premenopausal) of any age with any stage I-III hormone receptor positive breast cancer who are unable to receive tamoxifen due to a contraindication (i.e. thromboembolic disease or tamoxifen intolerance)
- May be given preoperatively as neoadjuvant therapy in premenopausal women with hormone receptor positive breast cancer who are unsuitable for immediate surgery or preoperative chemotherapy and who are unable to receive tamoxifen due to a contraindication (i.e. thromboembolic disease or tamoxifen intolerance)
- For all other indications, a BC Cancer “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment (please refer to [https://cap.phsa.ca/](https://cap.phsa.ca/)).

**EXCLUSIONS:**
- Patients older than 35 years of age who do not receive neoadjuvant or adjuvant chemotherapy and do not have a contraindication to tamoxifen.
- Hormone receptor negative breast cancer.
- Stage IV breast cancer (refer to BRAVLHRHAI)

**TESTS:**
- Bone density study before or after 2-3 months of therapy.
- Bone density every 2-3 years (refer to local osteoporosis guidelines).
- Consider intermittently testing LH, FSH, and serum estradiol levels in overweight women as ovarian suppression with LHRH agonists can be less effective in this population.
- If clinically indicated: serum cholesterol and triglycerides.
**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BC Cancer Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>anastrozole or letrozole or exemestane</td>
<td>1 mg daily x 5 years</td>
<td>2.5 mg daily x 5 years</td>
</tr>
<tr>
<td>buserelin (base) depot (SUPREFACT DEPOT®) or goserelin (ZOLADEX®) or leuprolide (LUPRON®)</td>
<td>6.3 mg every 6 weeks x 2 treatments then every 8 weeks x 5 years</td>
<td>3.6 mg every 4 weeks x 5 years</td>
</tr>
</tbody>
</table>

Surgical oophorectomy can be considered in older pre-menopausal women who do not want to preserve their fertility and who are tolerating the menopausal side effects of therapy.

*Once response has been established, the following long-acting agents may be substituted at the physician’s discretion for a total of 5 years of therapy. Menstrual function, and if necessary, hormone levels can be monitored to ensure effective dosing.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BC Cancer Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>buserelin (base) depot (SUPREFACT DEPOT®) or goserelin (ZOLADEX®) or leuprolide (LUPRON®)</td>
<td>9.45 mg every 12 weeks</td>
<td>10.8 mg every 12 weeks</td>
</tr>
</tbody>
</table>

Warning: The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is at your own risk and is subject to BC Cancer’s terms of use available at www.bccancer.bc.ca/terms-of-use.
PRECAUTIONS:

1. **Hepatic dysfunction:** Aromatase inhibitors are considered safe in mild-to-moderate hepatic dysfunction but have not been studied in severe hepatic dysfunction.

2. **Bone density:** The long-term effects of aromatase inhibitors on bone density in adjuvant therapy patients are unknown. Supplementation with calcium, vitamin D and regular weight bearing exercise is recommended. A bisphosphonate or RANK ligand inhibitor should be considered if clinically indicated. Caution in patients with an already established diagnosis of clinically significant osteoporosis.

3. **Hyperlipidemia:** An increase in cholesterol or triglyceride levels may occur when an aromatase inhibitor is initiated. Levels may need to be checked during the first few months of therapy, especially in those patients with prior significant lipid elevations.

Call Dr. Vanessa Bernstein or tumour group delegate at (250) 519-5500 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References:


